Analysis of Cyclooxygenase 2 (COX-2) Expression During Malignant Melanoma Progression
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Cyclooxygenase 2 (COX-2) is an inducible enzyme involved in the production of prostaglandins and thromboxanes during inflammation. There are now several lines of evidence indicating that increased expression of COX-2 plays a functional role in the development and progression of malignant epithelial cancers. However, there is only limited data regarding the role of COX-2 in melanoma pathogenesis. In the present work, we retrospectively examined lesions through out the development of melanoma and metastatic disease (dysplastic nevi n = 10, melanoma in situ n = 4, stage II melanoma n = 10, stage III n = 4, stage IV n = 3, stage V n = 2, melanoma metastasis lymph nodes n = 13 metastasis to other sites n = 3). COX-2 was consistently observed in keratinocytes, dermal fibroblasts, and inflammatory cells in regions adjacent to benign evi and primary cutaneous melanomas. However, no COX-2 staining was detected in the nevi nor in the primary skin melanoma cells. In addition, COX-2 was undetected in all vertical and radial growth phase cases Interestingly, 13 out of 13 of the lymph node metastasis expressed extremely high levels of COX-2 in overlying epithelium and inflammatory cells, and COX-2 was strongly detected in the metastatic cancer cells per se. For additional information on the expression of COX-2 in malignant melanoma, we determined the expression of COX-2 protein in several different melanoma cell lines. We found that 3We found that 5 out of 7 of the melanoma cells over expressed COX-2 compared to normal melanocytes. Collectively, these data suggest that COX-2 may play a functional role in metastases of melanoma, and treatment with COX-2 inhibitors may be efficacious for malignant melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cyclooxygenase regulates angiogenesis induced by colon cancer cells
Tsujii, M., Kawano, S., Tsuji, S., Sawaoka, H., Hori, M., & DuBois, R. N. (1998) · Cell · doi:10.1016/s0092-8674(00)81433-6 · Cited by 2,272
COX-3: in the wrong frame in mind
Dinchuk, J. E., Liu, R. Q., & Trzaskos, J. M. (2003) · Immunology Letters · doi:10.1016/s0165-2478(02)00268-7 · Cited by 100
Cited by
Inflammation and cancer: how hot is the link?
Aggarwal, B. B., Shishodia, S., Sandur, S. K., Pandey, M. K., & Sethi, G. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.06.029 · Cited by 1,312
Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity
Zelenay, S., van der Veen, A. G., Böttcher, J. P., Snelgrove, K. J., Rogers, N., Acton, S. E., Chakravarty, P., Girotti, M. R., Marais, R., Quezada, S. A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.015 · Cited by 1,128
Azad, M. B., Chen, Y., & Gibson, S. B. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2008.2270 · Cited by 760
Role of the unfolded protein response in cell death
Kim, R., Emi, M., Tanabe, K., & Murakami, S. (2006) · Apoptosis · doi:10.1007/s10495-005-3088-0 · Cited by 468
Multifaceted link between cancer and inflammation
Sethi, G., Shanmugam, M. K., Ramachandran, L., Kumar, A. P., & Tergaonkar, V. (2012) · Bioscience Reports · doi:10.1042/bsr20100136 · Cited by 333
De Cicco, P., Ercolano, G., & Ianaro, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01680 · Cited by 332
Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity
Balsamo, M., Scordamaglia, F., Pietra, G., Manzini, C., Cantoni, C., Boitano, M., Queirolo, P., Vermi, W., Facchetti, F., Moretta, A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906481106 · Cited by 330
Ackermann, J., Frutschi, M., Kaloulis, K., McKee, T., Trumpp, A., & Beermann, F. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2970 · Cited by 306
AMPK‐mediated autophagy inhibits apoptosis in cisplatin‐treated tumour cells
Harhaji‐Trajkovic, L., Vilimanovich, U., Kravic‐Stevovic, T., Bumbasirevic, V., & Trajkovic, V. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00663.x · Cited by 189
COX-2 expression positively correlates with PD-L1 expression in human melanoma cells
Botti, G., Fratangelo, F., Cerrone, M., Liguori, G., Cantile, M., Anniciello, A. M., Scala, S., D’Alterio, C., Trimarco, C., Ianaro, A., et al. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1150-7 · Cited by 104
“In melanoma COX-2 is shown to be expressed in both primary and metastatic lesions and its expression correlates with pathological features of primary tumors and patient’s prognosis [28, 50, 51].”
Müller-Decker, K. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9306-z · Cited by 73
“While one study failed to detect COX-2 expression in melanomas [127], a moderate to strong expression of COX2 is documented in numerous other studies for primary and metastatic melanomas as compared to no, or at best very weak, expression in benign nevi and normal epithelium [128–131].”
Gledhill, K., Rhodes, L. E., Brownrigg, M., Haylett, A. K., Masoodi, M., Thody, A. J., Nicolaou, A., & Tobin, D. J. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00696.x · Cited by 50
“Cyclooxygenase-2 protein was very weak to detect by immunofluorescence in EM in the current study, which concurs with findings of Goulet et al. (2003) who were also unable to detect COX-2 protein in EM.”
Result
Metadata
- Authors
- Goulet, A.-C., Einsphar, J. G., & Alberts, D. S.
- Venue
- Cancer Biology & Therapy
- Publisher
- Informa UK Limited
- Published
- 2003-11-01
- Volume
- 2
- Issue
- 6
- Pages
- 711-716
- ISSN
- 1538-4047 (ISSN-L)
- OpenAlex
- W2090604832
- Cited by
- 141
- References
- 2
- FWCI
- 4.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.